Education
About Us
Working with TipRanks
Follow Us
Vivesto AB (SE:VIVE)
:VIVE
VIVE Stock Chart & Stats
kr0.08
>-kr0.01(-0.59%)
At close: 4:00 PM EST
kr0.08
>-kr0.01(-0.59%)
Day’s Range― - ―
52-Week Rangekr0.07 - kr0.28
Previous CloseN/A
Volume772.68K
Average Volume (3M)410.92K
Market Cap
kr89.68M
Enterprise Valuekr50.45M
Total Cash (Recent Filing)kr2.10M
Total Debt (Recent Filing)kr13.00M
Price to Earnings (P/E)―
Beta-0.24
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,107,137,000
10 Day Avg. Volume214,919
30 Day Avg. Volume410,918
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.58
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company’s low debt burden provides durable financial flexibility: manageable interest and principal obligations reduce refinancing risk and preserve capacity to fund R&D or clinical programs. Over months this lowers bankruptcy risk and supports strategic options despite cash burn.
Oncology Delivery/formulation FocusA specialized focus on oncology and drug-delivery/formulation is a structural advantage: deep technical expertise and a platform approach can create differentiated products, licensing or partnership opportunities, and longer product lifecycles versus undifferentiated generics.
Improving Operating Cash Flow TrendA materially smaller operating cash outflow year-over-year indicates early operational stabilization or cost efficiency gains. If sustained, this trend can extend runway, reduce near-term financing needs, and demonstrate organizational ability to control burn across development cycles.
Bears Say
Persistent Net LossesRecurring multi-year losses erode capital and force reliance on external funding. Persistent negative earnings limit reinvestment, weaken investor confidence, and create ongoing pressure to secure dilutive financing or partnerships to sustain clinical and regulatory programs.
No Reported Revenue In Recent YearsThe absence of reported revenue for consecutive years signals loss of commercial scale or halted product sales, reducing visibility into sustainable margins and cash generation. This structural lack of operating revenue increases dependency on financing or asset monetization.
Eroding Equity BaseA marked decline in shareholders' equity over several years indicates accumulated losses and a shrinking capital cushion. This weakens the company’s ability to absorb setbacks, meet regulatory or commercial obligations, and may force dilutive capital raises under stressed conditions.
Vivesto AB News
VIVE FAQ
What was Vivesto AB’s price range in the past 12 months?
Vivesto AB lowest stock price was kr0.07 and its highest was kr0.28 in the past 12 months.
What is Vivesto AB’s market cap?
Vivesto AB’s market cap is kr89.68M.
When is Vivesto AB’s upcoming earnings report date?
Vivesto AB’s upcoming earnings report date is May 21, 2026 which is in 80 days.
How were Vivesto AB’s earnings last quarter?
Vivesto AB released its earnings results on Feb 12, 2026. The company reported -kr0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.015.
Is Vivesto AB overvalued?
According to Wall Street analysts Vivesto AB’s price is currently Overvalued.
Does Vivesto AB pay dividends?
Vivesto AB does not currently pay dividends.
What is Vivesto AB’s EPS estimate?
Vivesto AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB have?
Vivesto AB has 1,107,137,000 shares outstanding.
What happened to Vivesto AB’s price movement after its last earnings report?
Vivesto AB reported an EPS of -kr0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Vivesto AB?
Currently, no hedge funds are holding shares in SE:VIVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivesto AB
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Technical Analysis
AlzeCure Pharma AB
―
Gabather AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―